Visfatin serum levels are increased in women with preeclampsia: A case-control study

References

• Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631–644.
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–1074.
   PubMed Web of Science ®Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–137.
   PubMed Web of Science ®Google Scholar
• LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008;51:982–988.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46:1243–1249.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Pearson G, Cutler J, Lindheimer M; NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003;41:437–445.
   PubMed Web of Science ®Google Scholar
• Thadhani RI, Johnson RJ, Karumanchi SA. Hypertension during pregnancy: a disorder begging for pathophysiological support. Hypertension 2005;46:1250–1251.
   PubMed Web of Science ®Google Scholar
• Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002;9:147–160.
   PubMed Web of Science ®Google Scholar
• Shaamash AH, Elsnosy ED, Makhlouf AM, Zakhari MM, Ibrahim OA, EL-dien HM. Maternal and fetal serum nitric oxide (NO) concentrations in normal pregnancy, pre-eclampsia and eclampsia. Int J Gynaecol Obstet 2000;68:207–214.
   PubMed Web of Science ®Google Scholar
• Serrano NC, Casas JP, Díaz LA, Páez C, Mesa CM, Cifuentes R, Monterrosa A, et al. Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. Hypertension 2004;44:702–707.
   PubMed Web of Science ®Google Scholar
• Tsukimori K, Fukushima K, Tsushima A, Nakano H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. Hypertension 2005;46:696–700.
   PubMed Web of Science ®Google Scholar
• Raijmakers MT, Dechend R, Poston L. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension 2004;44:374–380.
   PubMed Web of Science ®Google Scholar
• Roberts JM, Von Versen-Hoeynck F. Maternal fetal/placental interactions and abnormal pregnancy outcomes. Hypertension 2007;49:15–16.
   PubMed Web of Science ®Google Scholar
• Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004;70:223–232.
   PubMed Web of Science ®Google Scholar
• Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007;50:269–275.
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137–142.
   PubMed Web of Science ®Google Scholar
• Briana DD, Malamitsi-Puchner A. Reviews: adipocytokines in normal and complicated pregnancies. Reprod Sci 2009;16:921–937.
   PubMed Web of Science ®Google Scholar
• Briana DD, Boutsikou M, Baka S, Gourgiotis D, Marmarinos A, Hassiakos D, Malamitsi-Puchner A. Perinatal changes of plasma resistin concentrations in pregnancies with normal and restricted fetal growth. Neonatology 2008;93:153–157.
   PubMed Web of Science ®Google Scholar
• Malamitsi-Puchner A, Briana DD, Boutsikou M, Kouskouni E, Hassiakos D, Gourgiotis D. Perinatal circulating visfatin levels in intrauterine growth restriction. Pediatrics 2007;119:e1314–e1318.
   PubMed Web of Science ®Google Scholar
• Atègbo JM, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, Miled A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab 2006;91:4137–4143.
   PubMed Web of Science ®Google Scholar
• Lea RG, Howe D, Hannah LT, Bonneau O, Hunter L, Hoggard N. Placental leptin in normal, diabetic and fetal growth-retarded pregnancies. Mol Hum Reprod 2000;6:763–769.
   PubMed Web of Science ®Google Scholar
• Haugen F, Ranheim T, Harsem NK, Lips E, Staff AC, Drevon CA. Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. Am J Physiol Endocrinol Metab 2006;290:E326–E333.
   PubMed Web of Science ®Google Scholar
• Lappas M, Yee K, Permezel M, Rice GE. Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. J Endocrinol 2005;186:457–465.
   PubMed Web of Science ®Google Scholar
• Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, Cetin I, et al. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. Clin Endocrinol (Oxf) 2007;66:447–453.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–430.
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002;187:1051–1058.
   PubMed Web of Science ®Google Scholar
• Morgan SA, Bringolf JB, Seidel ER. Visfatin expression is elevated in normal human pregnancy. Peptides 2008;29:1382–1389.
   PubMed Web of Science ®Google Scholar
• Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lossner U, et al. Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol (Oxf) 2008;69:69–73.
   PubMed Web of Science ®Google Scholar
• Adali E, Yildizhan R, Kolusari A, Kurdoglu M, Bugdayci G, Sahin HG, Kamaci M. Increased visfatin and leptin in pregnancies complicated by pre-eclampsia. J Matern Fetal Neonatal Med 2009;22:873–879.
   PubMed Web of Science ®Google Scholar
• Hu W, Wang Z, Wang H, Huang H, Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand 2008;87:413–418.
   PubMed Web of Science ®Google Scholar
• Mazaki-Tovi S, Romero R, Kim SK, Vaisbuch E, Kusanovic JP, Erez O, Chaiworapongsa T, et al. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J Matern Fetal Neonatal Med 2010;23:857–868.
   PubMed Web of Science ®Google Scholar
• Mazaki-Tovi S, Vaisbuch E, Romero R, Kusanovic JP, Chaiworapongsa T, Kim SK, Nhan-Chang CL, et al. Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. J Matern Fetal Neonatal Med 2010;23:1119–1128.
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. American journal of obstetrics and gynecology 2000;183:S1–S22.
   Google Scholar
• Johnson RJ, Kanbay M, Kang DH, Sánchez-Lozada LG, Feig D. Uric acid: a clinically useful marker to distinguish preeclampsia from gestational hypertension. Hypertension 2011;58:548–549.
   PubMed Web of Science ®Google Scholar
• Wolak T, Sergienko R, Wiznitzer A, Paran E, Sheiner E. High Uric Acid Level During the First 20 Weeks of Pregnancy is Associated with Higher Risk for Gestational Diabetes Mellitus and Mild Preeclampsia. Hypertens Pregnancy 2010. (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, Schernthaner G. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci 2006;110:605–609.
   PubMed Web of Science ®Google Scholar
• Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M, Vatish M, et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007;50:1033–1037.
   PubMed Web of Science ®Google Scholar
• Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003;88:2393–2398.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, Levine RJ, Karumanchi SA. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension 2004;43:988–992.
   PubMed Web of Science ®Google Scholar
• Wolf M, Sandler L, Muñoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002;87:1563–1568.
   PubMed Web of Science ®Google Scholar
• Pepene CE Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012 Jan;76 (1):119–25.
   PubMed Web of Science ®Google Scholar
• Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010;21:530–535.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology (Carlton) 2010;15:190–196.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009;41:150–153.
   PubMed Web of Science ®Google Scholar
• Mu J, Feng B, Ye Z, Yuan F, Zeng W, Luo Z, Qi W. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011;24:177–184.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008;23:959–965.
   PubMed Web of Science ®Google Scholar
• Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metab Clin Exp 2007;56:451–458.
   PubMed Web of Science ®Google Scholar
• Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008;69:878–884.
   PubMed Web of Science ®Google Scholar
• Zulfikaroglu E, Isman F, Payasli A, Kilic S, Kucur M, Danisman N. Plasma visfatin levels in preeclamptic and normal pregnancies. Arch Gynecol Obstet 2010;281:995–998.
   PubMed Web of Science ®Google Scholar